Skip to main content
Auro Laboratories Ltd. logo

Auro Laboratories Ltd. — Investor Relations & Filings

Ticker · 530233 ISIN · INE292C01011 LEI · 335800X1NEIR7EEPQC63 BSE.NS Manufacturing
Filings indexed 1 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country IN India
Listing BSE.NS 530233

About Auro Laboratories Ltd.

http://www.aurolabs.com

Auro Laboratories Ltd. specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. The company primarily focuses on the production of anti-diabetic drugs, with Metformin Hydrochloride being its flagship product. Its manufacturing facilities are compliant with World Health Organization Good Manufacturing Practices (WHO-GMP) and ISO standards, ensuring high-quality output for global markets. Auro Laboratories maintains a strong emphasis on research and development to optimize production processes and expand its product portfolio, which includes various specialty chemicals and therapeutic agents. The company provides cost-effective pharmaceutical solutions through integrated manufacturing capabilities and rigorous quality assurance protocols.

Recent filings

Filing Released Lang Actions
Auro Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
Regulatory Filings Classification · 85% confidence The document is a compliance letter under Regulation 29 of the SEBI Listing Regulations notifying the stock exchange of an upcoming Board meeting to consider audited financial results. It does not contain the results themselves, nor is it a proxy statement or dividend notice. It is a general regulatory announcement, so it falls under the fallback category of Regulatory Filings (RNS).
2026-05-25 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.